Indeed, in preclinical studies, imatinib therapy has normalised the tumour microenvironment by decreasing IFP, increasing transcapillary transport of oxygen and 51Cr-EDTA, and lowering VEGF and microvessel density (Pietras et al, 2001; Vlahovic et al, 2006). This evidence concerns the gene VEGFA and neoplasm.